Newborn screening for X-linked adrenoleukodystrophy: further evidence high throughput screening is feasible.
Mol Genet Metab
; 111(1): 55-7, 2014 Jan.
Article
en En
| MEDLINE
| ID: mdl-24268529
ABSTRACT
X-linked adrenoleukodystrophy (ALD) is characterized by adrenal insufficiency and neurologic involvement with onset at variable ages. Plasma very long chain fatty acids are elevated in ALD; even in asymptomatic patients. We demonstrated previously that liquid chromatography tandem mass spectrometry measuring C260 lysophosphatidylcholine reliably identifies affected males. We prospectively applied this method to 4689 newborn blood spot samples; no false positives were observed. We show that high throughput neonatal screening for ALD is methodologically feasible.
Palabras clave
ALD; AMN; Adrenal insufficiency; Adrenoleukodystrophy; Adrenomyeloneuropathy; LC MS/MS; Lyso-PC; MRI; Magnetic resonance imaging; NDBS; Newborn screening; Peroxisomal disorders; Tandem mass spectrometry; adrenoleukodystrophy; adrenomyeloneuropathy; liquid chromatography tandem mass spectrometry; lysophosphatidylcholine; newborn dried blood spots
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Lisofosfatidilcolinas
/
Tamizaje Neonatal
/
Adrenoleucodistrofia
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Screening_studies
Límite:
Female
/
Humans
/
Male
/
Newborn
Idioma:
En
Año:
2014
Tipo del documento:
Article